Search

Displaying results 701 - 710 of 10000 in total
  1. Drug

    Indocyanine green acid form

    go.drugbank.com/drugs/DB09374
    ApprovedInvestigational

    Each vial of Indocyanine Green for Injection USP contains 25 mg of Indocyanine Green as a sterile lyophilized powder with no more than 5% sodium iodide. … Indocyanine Green is a water soluble, tricarbocyanine dye with a peak spectral absorption at 800 nm.

  2. Drug

    Ropinirole

    go.drugbank.com/drugs/DB00268
    ApprovedInvestigational

    Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], [A174547]. … It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease.

  3. Drug

    Tigecycline

    go.drugbank.com/drugs/DB00560
    ApprovedInvestigational

    Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. … It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.

  4. Drug

    Ioxitalamic acid

    go.drugbank.com/drugs/DB13444
    ApprovedWithdrawn

    [A33006] Ioxitalamic acid in the salt forms of sodium and meglumine was developed by Liebel-Flarshem Canada Inc and approved by Health Canada in 1995. … [A27209] It is a first-generation contrast media formed by an ionic monomer with a high osmolarity of 1500-1800 mOsm/kg.

    Categories: X-Ray Contrast Media, Iodinated, Watersoluble, Nephrotropic, High Osmolar X-Ray Contrast Media
  5. Drug

    Polymyxin B

    go.drugbank.com/drugs/DB00781
    ApprovedInvestigationalVet approved

    Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. … It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of _Pseudomonas aeruginosa_[FDA Label].

    Mixtures: Bus and Classroom Yellow, Care Bus and Classroom Yellow
  6. Drug

    Isosorbide mononitrate

    go.drugbank.com/drugs/DB01020
    ApprovedInvestigational

    It is an anti-anginal agent that works by relaxing the smooth muscles of both arteries and veins, but but predominantly veins to reduce cardiac preload. … orally-administered isosorbide mononitrate is not rapid enough to offset an acute anginal episode.

  7. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    Lusutrombopag was approved by the FDA on July 31st, 2018 for the same therapeutic indication under the market name Mulpleta. … Higher percentages (65-78%) of the patients receiving lusutrombopag required no platelet transfusion prior to the primary invasive procedure compared to those receiving placebo [L4166].

  8. Drug

    Almasilate

    go.drugbank.com/drugs/DB13595
    Approved

    However its therapeutic efficacy is not comparable to other approved antacids, as it is no more effective in neutralizing acid and binding bile salts than other conventional antacids [A27138]. … It is a crystalline polyhydrate of aluminium/magnesium silicate and mediates its buffering activity by binding hydrogen ions within the polymer.

  9. Drug

    Risperidone

    go.drugbank.com/drugs/DB00734
    ApprovedInvestigational

    responsible for some of its undesirable effects. … [L12885] Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways

    Products: Nu-risperidone, Nb-risperidone
  10. Drug

    Vericiguat

    go.drugbank.com/drugs/DB15456
    ApprovedInvestigational

    cell types) that catalyze the synthesis of cyclic guanosine monophosphate (cGMP) in response to activation by nitric oxide (NO). … [L31178] Vericiguat was approved by the FDA in January 2021 - developed by Merck under the brand name Verquvo - for use in certain patients with systolic heart failure.